Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELARL PHARMACIE PORTE MUTIN : revenue, balance sheet and financial ratios

SELARL PHARMACIE PORTE MUTIN is a French company founded 16 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in SAINT-AMAND-MONTROND (18200), this company of category PME shows in 2017 a revenue of 2.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE PORTE MUTIN (SIREN 521855049)
Indicator 2024 2023 2022 2021 2020 2019 2017
Revenue N/C N/C N/C N/C N/C N/C 2 288 570 €
Net income 83 498 € 145 142 € 132 610 € 85 579 € 126 623 € 122 422 € 53 737 €
EBITDA N/C N/C N/C N/C N/C N/C 52 100 €
Net margin N/C N/C N/C N/C N/C N/C 2.3%

Revenue and income statement

In 2024, SELARL PHARMACIE PORTE MUTIN generates positive net income of 83 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2024: 54 k€ -> 83 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

83 498 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 76%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 49%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

75.873%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

49.463%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

54.9%

Solvency indicators evolution
SELARL PHARMACIE PORTE MUTIN

Sector positioning

Debt ratio
75.87 2024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Average -7 pts over 3 years

In 2024, the debt ratio of SELARL PHARMACIE PORTE MUTIN (75.87) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
49.46% 2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average +8 pts over 3 years

In 2024, the financial autonomy of SELARL PHARMACIE PORTE MUTIN (49.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 167.75. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

167.755

Liquidity indicators evolution
SELARL PHARMACIE PORTE MUTIN

Sector positioning

Liquidity ratio
167.75 2024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Average -16 pts over 3 years

In 2024, the liquidity ratio of SELARL PHARMACIE PORTE MUTIN (167.75) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELARL PHARMACIE PORTE MUTIN

Positioning of SELARL PHARMACIE PORTE MUTIN in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of SELARL PHARMACIE PORTE MUTIN is estimated at 1 165 693 € (range 811 770€ - 1 743 944€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
811k€ 1165k€ 1743k€
1 165 693 € Range: 811 770€ - 1 743 944€
NAF 5 année 2024

Valuation method used

Net Income Multiple
83 498 € × 14.0x = 1 165 694 €
Range: 811 771€ - 1 743 945€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE PORTE MUTIN with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE PORTE MUTIN

What is the revenue of SELARL PHARMACIE PORTE MUTIN ?

The revenue of SELARL PHARMACIE PORTE MUTIN in 2017 is 2.3 M€.

Is SELARL PHARMACIE PORTE MUTIN profitable?

Yes, SELARL PHARMACIE PORTE MUTIN generated a net profit of 83 k€ in 2024.

Where is the headquarters of SELARL PHARMACIE PORTE MUTIN ?

The headquarters of SELARL PHARMACIE PORTE MUTIN is located in SAINT-AMAND-MONTROND (18200), in the department Cher.

Where to find the tax return of SELARL PHARMACIE PORTE MUTIN ?

The tax return of SELARL PHARMACIE PORTE MUTIN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE PORTE MUTIN operate?

SELARL PHARMACIE PORTE MUTIN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.